Skip to content
DataLookout
Menu

NCT07667335

Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 4 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Start date changed from estimate of Oct 15, 2026 to Oct 20, 2026
  2. Notable Eligibility criteria shortened, about 4 words
  3. Notable Recruitment opened Show 4 more changesShow less
    • Eligibility criteria expanded, about 45 words
    • Start date moved earlier from Dec 1, 2026 to Oct 15, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
    • Site details revised
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Incidence of treatment related adverse events (Phase Ib)
Timeframe: From baseline, up to 21 days after last dose of investigational product
Overall response rate (ORR) (Phase II)
Timeframe: From baseline, up to disease progression or unacceptable side effects, up to 3 years after completion of study treatment

Secondary (5)

ORR (Phase Ib)
Complete response rate (Phase II)
Duration of response (Phase II)
Progression free survival (Phase II)
Rate of consolidative therapy with cystectomy or chemoradiation with stage 3b (Phase II)

Arms and interventions

Treatment (enfortumab vedotin, pembrolizumab, quemliclustat)Experimental

Patients receive quemliclustat IV on day 1, enfortumab vedotin IV on days 1 and 8 and pembrolizumab IV on day 1 of each cycle. Cycles repeat every 21 days for 2 years in the absence of disease progression or unacceptable toxicity. Patients may undergo tumor biopsy during screening and optionally undergo throughout the study. Patients also undergo CT/MRI and blood sample collection throughout the study.

Drugs: Quemliclustat, Enfortumab Vedotin

Procedures: Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Biopsy Procedure

Biologicals: Pembrolizumab

Sites

1 site in 1 country

  • Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States